New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
17:50 EDTARWR, ALNYArrowhead Research reiterates patent position
Arrowhead Research (ARWR) reaffirmed its belief that it has broad access to intellectual property required to develop ARC-520, its clinical candidate against chronic hepatitis B infection. Arrowhead does not believe there are additional unlicensed patents directed to RNAi therapeutics targeting the hepatitis B virus that affect its freedom to operate. The company signed a license agreement with Alnylam Pharmaceuticals (ALNY) in January 2012, giving it access to intellectual property that enables the discovery, development, and commercialization of an RNAi therapeutic targeting the hepatitis B virus. Arrowhead holds multiple levels of patent protection on ARC-520 including U.S. Patent Nos. 8,313,772 and 8,501,930 covering the Dynamic Polyconjugate delivery system, and U.S. Patent Application number 13/535,454 covering ARC-520ís siRNA component, which was recently allowed by the U.S. Patent and Trademark Office. Arrowhead and its legal advisors continually review the patent landscape to ensure freedom to operate and the company believes that development and commercialization of ARC-520 would not infringe patents governing RNAi therapeutics targeting the hepatitis B virus, including U.S. Patent No. 8,618,277 in the McSwiggen patent estate.
News For ARWR;ALNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 28, 2014
08:10 EDTALNYAlnylam, The Medicines Co. file application to initiate Phase 1 ALN-PCSsc study
Subscribe for More Information
October 27, 2014
07:04 EDTALNYAlnylam management to meet with Deutsche Bank
Subscribe for More Information
October 24, 2014
07:31 EDTARWRArrowhead management to meet with Deutsche Bank
Subscribe for More Information
October 23, 2014
07:44 EDTARWRArrowhead management to meet with Deutsche Bank
Meetings to be held in Minneapolis/Chicago on October 23 hosted by Deutsche Bank.
October 21, 2014
09:48 EDTALNYShire could target BioMarin, TheStreet's Feuerstein says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use